drugset / Trial / NCT02887443
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate
NaSingle-groupOpen-labelOther
Summary
This phase I open label study is conducted to assess the potential pharmacokinetic interaction of Raxone® with midazolam in healthy male volunteers
Timeline
- Start
- 2016-09
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idebenone | Small molecule | 300 mg | — |
| Subject | Midazolam | Small molecule | 2.5 mg | Oral |
Indications
No indication recorded.